Benzinga | Dec 20, 2021 04:53AM EST

SVB Leerink Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $200

SVB Leerink analyst Marc Goodman maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and lowers the price target from $230 to $200.